Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions
2018年10月11日 - 6:00PM
ビジネスワイヤ(英語)
Patient-centric website ‘Life Effects’ European
launch sees expanded content featuring insights from European
patients with chronic conditions
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the European launch of Life Effects, a patient-centric
website hosting content created by patients and checked by experts,
at the European Committee for the Treatment and Research of
Multiple Sclerosis (ECTRIMS) Congress in Berlin.
This online content initiative was created following extensive
research from 13,500 patients globally and is now being launched in
Europe. Research shows a demand from patients especially those with
chronic conditions including Multiple Sclerosis (MS), for
trustworthy and reliable health information.1
With content developed in collaboration with patients, Life
Effects consists of articles, videos and podcasts that offer
information, insight and inspiration to people suffering from one
or more chronic condition, including MS, particularly focusing on
the impact a condition has on a patient’s day-to-day life. By
working with a core group of patients on an ongoing basis, who make
direct contributions which are reviewed by experts, Life Effects
offers a first-hand, credible perspective on what it’s like to live
with a chronic condition. Together, these patients and Life Effects
tell authentic stories, take a patient-centric look at the latest
thinking, and offer practical tips and advice to make things a
little easier.
Aoife Kirwan, who is living with MS and based in Ireland said:
“It’s always exciting when an opportunity arises for the voices of
people with MS to be heard. Life Effects was developed in
collaboration with people living with chronic conditions including
MS, which means that it is created by us, for us. It allows people
living with chronic conditions the chance to share our stories,
thoughts and opinions while knowing that the information is also
checked by experts. In an age where endless amounts of information
is readily available, this reliable information from people with
the same condition is invaluable to patients. As someone living
with MS, I am delighted to see such a collaboration between my
community and the medical community which offers a new resource
that combines lived experience with scientific fact.”
Vice President of Medical Affairs at Teva Europe, Marco Avila
said: “Life Effects is the result of addressing an unmet need for
trustworthy online health information, particularly for patients
living with a chronic condition, by capturing what it’s really like
to live with these conditions and hearing directly from reliable
sources – the patients themselves. By creating content which
complements the patients’ medical journey with healthcare
professionals, the go-to when seeking information about diagnosis
and treatment options, we offer a greater insight into the impact
of these conditions on a daily basis. Life Effects is about content
for patients, by patients and reviewed by experts, offering a
reliable resource they can trust.”
The European launch of Life Effects marks the website’s
expansion outside the US and it now incorporates MS related
content, reflected in the choice of announcing at ECTRIMS. The
website also contains content on conditions including: asthma,
depression and migraine.
The Life Effects team works with Healthline, the fastest growing
consumer health information site, and Panoply, a premium podcast
network which is part of The Slate Group. Healthline and Panoply
help Teva integrate the authentic voice and credible point of view
of the patient with the rigorous editorial focus of the
professional journalist.
Vice President of Channels Strategy and Digital Content at Teva,
Arun Mahtani said: “Life Effects is a platform for patients to
provide support and advice to others living with a chronic
condition. At Teva, we are committed to empowering patients and
Life Effects is the true embodiment of this – hearing from the
patient voice directly with support from the experts. This content
is personal and meaningful for each individual and we have been
overwhelmed with the impact of this collaboration which offers
greater understanding of the challenges patients face outside of
treatment.”
-ENDS-
References
1. Edelman Intelligence 2018. Teva Brand Research
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global leader in generic medicines, with innovative treatments in
select areas, including CNS, pain and respiratory. We deliver
high-quality generic products and medicines in nearly every
therapeutic area to address unmet patient needs. We have an
established presence in generics, specialty, OTC and API, building
on more than a century-old legacy, with a fully integrated R&D
function, strong operational base and global infrastructure and
scale. We strive to act in a socially and environmentally
responsible way. Headquartered in Israel, with production and
research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of
patients. Learn more at www.tevapharm.com.
###
Date of Preparation: October 2018 | Ref: HQ/TV/18/0010
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181011005032/en/
TevaFiona Cohen, + 31 6 2008
2545Fiona.Cohen@Tevaeu.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024